Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1039P (RNA, U6 small nuclear 1039, pseudogene) is a non-coding RNA pseudogene derived from the U6 small nuclear RNA gene. U6 snRNA is an essential component of the spliceosome, which catalyzes pre-mRNA splicing in eukaryotes[1][3]. However, RNU6-1039P is a processed pseudogene, meaning it is a non-functional genomic sequence arising from the retrotransposition or duplication of the U6 snRNA gene, with considerable sequence similarity but lacking function due to mutations, truncations, or regulatory absence[2][5]. Pseudogenes like RNU6-1039P do not participate in cell signaling, regulatory functions, or disease pathways in a manner that would make them valid molecular targets for drug development. No evidence suggests that RNU6-1039P produces a functional transcript or protein, interacts with drugs, or is relevant for biomarker use or therapeutic safety. Such entries are mainly of interest for genomic annotation, evolutionary biology, and studies of gene and genome organization rather than biomedical research or drug discovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1039, pseudogene (RNU6-1039P).